ArticleBlood2011
The host genomic environment of the provirus determines the abundance of HTLV-1-infected T-cell clones.
Article in Blood, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 207 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
207 citing papers in PubMed, 320 citations in OpenAlex.
- Clinical trial of raltegravir, an integrase inhibitor, in HAM/TSP.Annals of clinical and translational neurology · 2021Trial
- Lentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency.Science translational medicine · 2016Trial
- Core nucleosomes are refractory to lentiviral DNA integration.Nature communications · 2026Article
- Loss of HTLV-1-specific CD8Blood neoplasia · 2026Article
- Integrated TCRγ Clonality Workflow for Molecular Diagnosis in HTLV-1 Carriers and Adult T-Cell Leukemia/Lymphoma.Diagnostics (Basel, Switzerland) · 2026Article
- The viral and host genomic landscape of human T-cell leukemia virus type I in Peru.Virology journal · 2026Article
- Adult T-cell Leukemia Following Satralizumab Treatment for Neuromyelitis Optica Spectrum Disorder.Internal medicine (Tokyo, Japan) · 2026Article
- From Genomic and Epigenomic Maps to Medicines in Adult T-Cell Leukemia/Lymphoma.Cancer science · 2026Review
- Review
- Case report:Frontiers in oncology · 2026Article
- Evolution of the HIV-1 integration site landscape and inducible reservoir in early-treated people.PLoS pathogens · 2025Article
- Clonality analysis of HTLV-1-infected cells enhances prognostic precision in smoldering adult T-cell leukemia/ lymphoma.Haematologica · 2025Article
- Advances in clonality analysis of human T-cell leukemia virus type 1-infected cells: from Southern blotting to high-throughput sequencing.Journal of clinical and experimental hematopathology : JCEH · 2025Review
- Intron-oriented HTLV-1 integration in an adult T-cell leukemia/lymphoma cell line sustains expression of intact ift81 mRNA.FEBS letters · 2025Article
- Circulating Cell-Free DNA of Bovine Leukemia Virus: A Promising Biomarker for Enzootic Bovine Leukosis.Microbiology and immunology · 2025Article
- Barcoded HIV-1 reveals viral persistence driven by clonal proliferation and distinct epigenetic patterns.Nature communications · 2025Article
- Rewired chromatin structure and epigenetic gene dysregulation during HTLV-1 infection to leukemogenesis.Cancer science · 2025Article
- Methodological landscape in the field of integration site identification of retroviruses and retroviral vectors.Frontiers in bioengineering and biotechnology · 2025Review
- Determinants in the HTLV-1 Capsid Major Homology Region that are Critical for Virus Particle Assembly.Journal of molecular biology · 2024Article
- Article
147 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
Abstract
Human T-lymphotropic virus type 1 (HTLV-1) persists by driving clonal proliferation of infected T lymphocytes. A high proviral load predisposes to HTLV-1-associated diseases. Yet the reasons for the variation within and between persons in the abundance of HTLV-1-infected clones remain unknown. We devised a high-throughput protocol to map the genomic location and quantify the abundance of > 91,000 unique insertion sites of the provirus from 61 HTLV-1(+) persons and > 2100 sites from in vitro infection. We show that a typical HTLV-1-infected host carries between 500 and 5000 unique insertion sites. We demonstrate that negative selection dominates during chronic infection, favoring establishment of proviruses integrated in transcriptionally silenced DNA: this selection is significantly stronger in asymptomatic carriers. We define a parameter, the oligoclonality index, to quantify clonality. The high proviral load characteristic of HTLV-1-associated inflammatory disease results from a larger number of unique insertion sites than in asymptomatic carriers and not, as previously thought, from a difference in clonality. The abundance of established HTLV-1 clones is determined by genomic features of the host DNA flanking the provirus. HTLV-1 clonal expansion in vivo is favored by orientation of the provirus in the same sense as the nearest host gene.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.